Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc A Pfeffer

Showing results (461-470 of 520) with videos related to

Pageof 52
Sort By:
JAMA|July 9, 2004
Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trialMichael A Blazing, James A de Lemos, Harvey D White, et al.
Circulation|January 22, 2024
Pulmonary Congestion and Left Ventricular Dysfunction After Myocardial Infarction: Insights From the PARADISE-MI TrialMark C Petrie, Jean L Rouleau, Brian Claggett, et al.
Circulation|September 1, 2024
Therapeutic Effects of Heart Failure Medical Therapies on Standardized Kidney Outcomes: Comprehensive Individual Participant-Level Analysis of 6 Randomized Clinical TrialsJawad H Butt, John J V McMurray, Brian L Claggett, et al.
Circulation. Heart Failure|August 15, 2014
Cardiac structure and function and prognosis in heart failure with preserved ejection fraction: findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) TrialAmil M Shah, Brian Claggett, Nancy K Sweitzer, et al.
European Heart Journal|July 20, 2022
Pharmacogenetics-guided dalcetrapib therapy after an acute coronary syndrome: the dal-GenE trialJean Claude Tardif, Marc A Pfeffer, Simon Kouz, et al.
Diabetes, Obesity & Metabolism|January 24, 2019
Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney diseaseDavid M Charytan, Scott D Solomon, Peter Ivanovich, et al.
American Heart Journal|May 13, 2015
Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placeboRhonda Bentley-Lewis, David Aguilar, Matthew C Riddle, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|June 9, 2009
Baseline characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)Marc A Pfeffer, Emmanuel A Burdmann, Chao-Yin Chen, et al.
Clinical Trials (London, England)|February 1, 2017
RejoinderThomas R Fleming, David L DeMets, Matthew T Roe, et al.
European Journal of Heart Failure|December 18, 2024
Association between body mass index and clinical outcomes in patients with acute myocardial infarction and reduced systolic function: Analysis of PARADISE-MI trial dataOffer Amir, Gabby Elbaz-Greener, Shemy Carasso, et al.
Pageof 52

Showing results (461-470 of 520) with videos related to

Sort By:
Pageof 52
JAMA|July 9, 2004
Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trialMichael A Blazing, James A de Lemos, Harvey D White, et al.
Circulation|January 22, 2024
Pulmonary Congestion and Left Ventricular Dysfunction After Myocardial Infarction: Insights From the PARADISE-MI TrialMark C Petrie, Jean L Rouleau, Brian Claggett, et al.
Circulation|September 1, 2024
Therapeutic Effects of Heart Failure Medical Therapies on Standardized Kidney Outcomes: Comprehensive Individual Participant-Level Analysis of 6 Randomized Clinical TrialsJawad H Butt, John J V McMurray, Brian L Claggett, et al.
Circulation. Heart Failure|August 15, 2014
Cardiac structure and function and prognosis in heart failure with preserved ejection fraction: findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) TrialAmil M Shah, Brian Claggett, Nancy K Sweitzer, et al.
European Heart Journal|July 20, 2022
Pharmacogenetics-guided dalcetrapib therapy after an acute coronary syndrome: the dal-GenE trialJean Claude Tardif, Marc A Pfeffer, Simon Kouz, et al.
Diabetes, Obesity & Metabolism|January 24, 2019
Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney diseaseDavid M Charytan, Scott D Solomon, Peter Ivanovich, et al.
American Heart Journal|May 13, 2015
Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placeboRhonda Bentley-Lewis, David Aguilar, Matthew C Riddle, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|June 9, 2009
Baseline characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)Marc A Pfeffer, Emmanuel A Burdmann, Chao-Yin Chen, et al.
Clinical Trials (London, England)|February 1, 2017
RejoinderThomas R Fleming, David L DeMets, Matthew T Roe, et al.
European Journal of Heart Failure|December 18, 2024
Association between body mass index and clinical outcomes in patients with acute myocardial infarction and reduced systolic function: Analysis of PARADISE-MI trial dataOffer Amir, Gabby Elbaz-Greener, Shemy Carasso, et al.
Pageof 52